<DOC>
	<DOC>NCT01978977</DOC>
	<brief_summary>Investigators propose to assess,the safety and tolerability profile (number of participants with adverse events)of bevacizumab (Avastin) when combined with standard chemotherapy as first line treatment of patients with metastatic Breast Cancer.</brief_summary>
	<brief_title>Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer</brief_title>
	<detailed_description>Nowadays in clinical practice patients with previously untreated metastatic breast cancer often receive taxane-based chemotherapy (paclitaxel or docetaxel) in combination with bevacizumab as it has been shown to increase progression-free survival. There is currently minimal information whether bevacizumab should be given as maintenance therapy after discontinuation of chemotherapy.</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Written informed consent Age ≥18 years Patients with histologically or cytologically confirmed, HER2negative, metastatic Breast Cancer No prior first line treatment for metastatic Breast Cancer Previous hormonotherapy for metastatic Breast Cancer is allowed One or more measurable lesions (≥1cm in diameter with spiral CT scan or ≥2cm with conventional techniques) according to RECIST criteria ECOG performance status ≤2 Adequate haematological, renal and hepatic function Urine protein &lt;2+ (dipstick) Life expectancy of ≥12 weeks Previous first line treatment for metastatic colorectal cancer(progression &gt;12 months after the end of adjuvant treatment) Previous radiotherapy to target lesions Patients with brain metastases and/or cancerous meningitis Presence or history of other neoplasm except properly treated basal cell skin cancer or in situ cervical carcinoma Patients participating in interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>mBC</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Anti-angiogenic agent</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>1st Line</keyword>
</DOC>